TOP > 外国特許検索 > NON-CANCEROUS LIVER FACTOR USEFUL IN DIAGNOSIS RELATING TO HEPATOCELLULAR CARCINOMA AND UTILIZATION THEREOF

NON-CANCEROUS LIVER FACTOR USEFUL IN DIAGNOSIS RELATING TO HEPATOCELLULAR CARCINOMA AND UTILIZATION THEREOF コモンズ

外国特許コード F160008736
整理番号 NU-654
掲載日 2016年4月28日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP054939
国際公開番号 WO 2016133212
国際出願日 平成28年2月19日(2016.2.19)
国際公開日 平成28年8月25日(2016.8.25)
優先権データ
  • 特願2015-030710 (2015.2.19) JP
発明の名称 (英語) NON-CANCEROUS LIVER FACTOR USEFUL IN DIAGNOSIS RELATING TO HEPATOCELLULAR CARCINOMA AND UTILIZATION THEREOF コモンズ
発明の概要(英語) Provided are a marker useful in diagnosis such as prognosis prediction or the like of hepatocellular carcinoma, and utilization thereof. The present teaching is a method for assisting diagnosis relating to prognosis prediction or the like of hepatocellular carcinoma, the method comprising a step for measuring the expression levels of the FAM3B (family with sequence similarity 3, member B) gene and/or the KRT23 (keratin 23 (histone deacetylase inducible)) gene. Useful information that assists diagnosis relating to prognosis prediction or the like of hepatocellular carcinoma can be obtained by measuring the expression levels of the FAM3B and/or KRT23 genes in the non-cancerous liver of an individual with a risk of hepatocellular carcinoma or an individual suffering from hepatocellular carcinoma.
特許請求の範囲(英語) [claim1]
1. Being the method of assisting the diagnosis regarding the liver cell cancer,
FAM3B (family with sequence similarity 3, member B) gene and/or KRT23 (keratin 23 (histone deacetylase inducible))The process which measures the revelation level of the gene,
It has, method.
[claim2]
2. The aforementioned FAM3B gene of the background liver and/or revelation level of the aforementioned KRT23 gene is measured, in claim 1 method of statement.
[claim3]
3. The aforementioned FAM3B gene of the background liver of the liver cell cancer affection individual and/or measuring the revelation level of the aforementioned KRT23 gene, it assists the development of the liver cell cancer, the recurrence of the liver cell cancer and the diagnosis regarding convalescence, in claim 1 or 2 method of statement.
[claim4]
4. The aforementioned FAM3B gene of the background liver of the liver cell cancer risk individual and/or measuring the revelation level of the aforementioned KRT23 gene, it assists the diagnosis regarding the emergence risk of the liver cell cancer or the development to the liver cell cancer, in claim 1 or 2 method of statement.
[claim5]
5. The aforementioned FAM3B gene of the background liver and/or time-dependant change of revelation level of the aforementioned KRT23 gene or the aforementioned FAM3B gene and/or revelation level of the aforementioned KRT23 gene is contrasted with specified reference level, in either of the claim 1-4 method of statement.
[claim6]
6. Being the method of assisting the diagnosis regarding the liver cell cancer,
FAM3B in the liquid characteristic component which was picked from the liver cell cancer affection individual or the liver cell cancer risk individual (family with sequence similarity 3, member B) the gene and/or KRT23 (keratin 23 (histone deacetylase inducible))The process which measures the revelation level of the gene,
The method of having.
[claim7]
7. The aforementioned liquid characteristic component the blood includes part at least, in claim 6 method of statement.
[claim8]
8. Being the marker for diagnosing regarding the liver cell cancer,
FAM3B (family with sequence similarity 3, member B) gene and/or KRT23 (keratin 23 (histone deacetylase inducible))It is the gene product of the gene, the marker.
[claim9]
9. Being the diagnostic medicine for diagnosing regarding the liver cell cancer,
FAM3B (family with sequence similarity 3, member B) gene and/or KRT23 (keratin 23 (histone deacetylase inducible))The reagent in order to measure the revelation level of the gene is included, the diagnostic medicine.
[claim10]
10. Being the kit for diagnosing regarding the liver cell cancer,
FAM3B (family with sequence similarity 3, member B) gene and/or KRT23 (keratin 23 (histone deacetylase inducible))In order to measure the revelation level of the gene or more the reagent of 1 or 2 is included, the kit.
[claim11]
11. Being the diagnostic medicine for diagnosing regarding the liver cell cancer,
FAM3B (family with sequence similarity 3, member B) and/or KRT23 (keratin 23 (histone deacetylase inducible))The reagent in order to measure is included, the diagnostic medicine.
[claim12]
12. The aforementioned reagent the description above FAM3B and/or is the antibody which recognizes the description above KRT23 uniquely, in claim 11 the diagnostic medicine of statement.
[claim13]
13. Being the kit for diagnosing regarding the liver cell cancer,
FAM3B (family with sequence similarity 3, member B) and/or KRT23 (keratin 23 (histone deacetylase inducible))In order to measure or more the reagent of 1 or 2 is included, the kit.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NAGOYA UNIVERSITY
  • 発明者(英語)
  • NOMOTO SHUJI
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
名古屋大学の公開特許情報を掲載しています。ご関心のある案件がございましたら、下記まで電子メールでご連絡ください。

PAGE TOP

close
close
close
close
close
close